neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II

2003 ◽  
Vol 21 (3) ◽  
pp. 399-400 ◽  
Author(s):  
Kathleen I. Pritchard ◽  
Mark N. Levine ◽  
Dongsheng Tu
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Premenopausal Women ◽  
Adjuvant Breast Cancer ◽  
Cancer Setting

scholarly journals The role of hormonal ovarian ablation in adjuvant treatment of premenopausal breast cancer

2011 ◽  
Vol 139 (5-6) ◽  
pp. 339-346
Author(s):  
Zafir Murtezani ◽  
Zora Neskovic-Konstantinovic ◽  
Natasa Stanisavljevic ◽  
Vladimir Kovcin
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Steroid Receptors ◽  
Premenopausal Women ◽  
Small Sample ◽  
Malignant Tumours ◽  
Group 13 ◽  
Ovarian Ablation ◽  
Fac Chemotherapy ◽  
Lh Rh

Introduction. Breast cancer is the most frequent malignant disease in women with about 25% compared to all malignant tumours. Chemotherapy, antiestrogen and ovarian ablation/ supression present effective adjuvant approach for premenopausal women diagnosed with hormonal depended, operable breast cancer. Objective. To evaluate benefits of combined chemo/hormonal therapy that is undutiful, but optimal application has not yet been clearly determined. Methods. Thirty-six women were divided into three therapy groups. The first group (13 women) was treated with six cycles of adjuvant FAC chemotherapy followed by regular check-ups; the second group (13 women) after six cycles of adjuvant FAC chemotherapy continued treatment with a two-year application of goserelin given by subcutaneous injections (FAC-Z); the third group (10 women), after six cycles of adjuvant FAC chemotherapy continued with once per month application of gorselin for two years and a daily application of 20 mg tamoxifen for five years (FAC-Z-T). The length of overall disease free period and survival were analyzed in all three groups. Results. The benefit of LH-RH analogues in premenopausal women with hormone-dependent breast cancer was found to be low, and probably limited to smaller subgroups of patients, possibly such as those with either both steroid receptors positive (ER and PR) or those with an extremely high level of steroid receptors. In our paper, analyses of such subgroups could not been performed due to a small sample of patients. The effect of therapy is better in patients, who developed amenorrhoea, regardless of the type of later hormonal therapy. Conclusion. Ovarial ablation, whatever the method, should be probably applied as early as possible within the treatment of early breast cancer, especially in patients in whom chemotherapy induced amenorrhoea is not expected, i.e. in very young female patients.

Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment

2017 ◽  
pp. 116-122
Author(s):  
Michael Gnant ◽  
Catherine Van Poznak ◽  
Lowell Schnipper
Keyword(s):  
Breast Cancer ◽  
Bisphosphonate Therapy ◽  
Value Assessment ◽  
A Value ◽  
Breast Cancer Outcomes ◽  
Primary Endpoints ◽  
Adjuvant Breast Cancer ◽  
Pros And Cons ◽  
Cancer Setting ◽  
Meta Analyses

Clinical trials and meta-analyses investigating bisphosphonates as an adjuvant breast cancer therapy have shown a consistent trend, with postmenopausal women and women receiving ovarian suppression with gonadotropin-releasing hormone therapy gaining improved breast cancer outcomes with the use of adjuvant bisphosphonate therapy. The interpretation of these data is controversial, because the primary endpoints of the majority of adjuvant bisphosphonate studies have been negative. Pros and cons as well as the value of adjuvant bisphosphonate therapy are discussed here.

scholarly journals Cost-Utility Analysis of Newer HER2- Testing Technologies to Target Trastuzumab in the Adjuvant Breast Cancer Setting

2014 ◽  
Vol 17 (3) ◽  
pp. A90
Author(s):  
I.L. Ferrusi ◽  
N.A. Kulin ◽  
R. Goeree ◽  
N. Leighl ◽  
E.M. Pullenayegum ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Her2 Testing ◽  
Adjuvant Breast Cancer ◽  
Cancer Setting

Weight changes in breast cancer survivors who received adjuvant antiestrogen therapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6588-6588
Author(s):  
B. M. Harris ◽  
A. C. Broxson ◽  
L. A. Anderson ◽  
J. G. Engelbrink ◽  
M. A. Zalewski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Weight Gain ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Estrogen Therapy ◽  
Premenopausal Women ◽  
Weight Changes ◽  
Menopausal Women ◽  
Antiestrogen Therapy ◽  
Post Menopausal

6588 Background: Antiestrogen therapy has dramatically improved breast cancer survival rates but weight gain may be problematic. Studies evaluating antiestrogen therapy-related weight gain have yielded mixed results. Our primary objective was to evaluate weight changes in female breast cancer survivors (BCS) who received adjuvant anti-estrogen therapy for stage 0-III breast cancer. Methods: A retrospective chart review was conducted to evaluate weight changes in female chemo naive BCS receiving anti-estrogen therapy. Weights at initiation of hormonal therapy and at 6, 12, 24, and 36 months of follow-up were recorded. Median weight changes were calculated and were compared with Wilcoxon's signed rank test or the Kurskall-Wallis test. Results: A total of 622 women were included. The majority were white (77%), had stage I disease (78%), and were postmenopausal (82%). The median age at diagnosis was 59 years (range, 26–87). Median weight at initiation of hormonal therapy among premenopausal women was 65 kg (range 45.4–122.9). Median weight gain in this group was 0.4 kg (p = 0.009), 0.7 kg (p = 0.013), 1.9 kg (p = 0.0001), and 2.4 kg (p < 0.0001) at 6, 12, 24, and 36 months respectively. Among post-menopausal women, median weight at initiation of therapy was 71.7 kg (range 41.5–152.0) and median weight gain was 0.5 kg (p < 0.0001), 1 kg (p < 0.0001), 0.85 kg (p = 0.001), and 0.85 kg (p = 0.004) at 6, 12, 24, and 36 months respectively. Premenopausal patients had significantly more weight gain at 24 (p = 0.041) and 36 months (p = 0.005), as compared to postmenopausal patients. Among premenopausal women, 110/111 were treated with tamoxifen. Among post-menopausal women (n = 510), hormonal therapy was as follows: unknown n = 28 patients, tamoxifen n = 312, and AI n = 170. Overall, BCS treated with tamoxifen vs an AI had significantly more weight gain at 24 (p = 0.003) and 36 months (p = 0.009). Conclusions: Premenopausal patients are at higher risk for weight gain than postmenopausal patients. Further prospective research is warranted examining weight gain as a long-term side effect of anti-estrogen therapy in BCS. No significant financial relationships to disclose.

scholarly journals Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Cristina Silva ◽  
Ana Cristina Ribeiro Rama ◽  
Sérgio Reis Soares ◽  
Mariana Moura-Ramos ◽  
Teresa Almeida-Santos
Keyword(s):  
Breast Cancer ◽  
Reproductive Health ◽  
Health Outcomes ◽  
Young Women ◽  
Hormonal Therapy ◽  
Ovarian Function ◽  
Premenopausal Women ◽  
Systemic Treatments ◽  
Future Fertility

Abstract Background Breast cancer is the most common cancer in young women. Fortunately current survival rates of BC are significant which makes future fertility very important for quality of life of BC survivors. Chemotherapy carries a significant risk of infertility in BC patients so it is important to support fertility preservation decisions in premenopausal women. Amenorrhea has long been used as a surrogate marker of infertility in cancer patients but more reliable ovarian reserve (OR) markers are available. This study aimed to prospectively measure levels of OR in a cohort of young women with breast cancer exposed to chemotherapy, to identify adverse reproductive health outcomes in this population and to assess the influence of patient and treatment-related factors in those outcomes. Methods This prospective observational study included premenopausal women with breast cancer aged 18–40 years at diagnosis and proposed for (neo) adjuvant chemotherapy. Patients were evaluated before, during and a minimum of 9 months after the end of chemotherapy. Reproductive health outcomes: menses, hormonal and ultrasound OR markers, recovery of ovarian function and Premature Ovarian Insufficiency (POI). Results A total of 38 patients were included (mean age 32.9 ± 3.5 years). Levels of OR significantly decreased during the study. At the last follow up, 35 patients had AMH below the expected values for age; eight presented postmenopausal FSH; ten had not recovered their ovarian function and five met the defined criteria for POI. Age and baseline AMH were positively correlated with AMH at the last follow-up. AMH levels were higher in the group of patients treated with trastuzumab and lower in those under hormonal therapy, at the last follow-up. Conclusions Significant effects of systemic treatments on several reproductive outcomes and a strong relation of those outcomes with patient’s age and baseline level of AMH were observed. Our results point to a possible lower gonadotoxicity when treatment includes targeted therapy with trastuzumab. Also, this investigation highlights the lack of reliable OR markers in women under hormonal therapy.

scholarly journals Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study

2021 ◽  
Vol 20 ◽  
pp. 153473542110637
Author(s):  
Kerstin Faravel ◽  
Marie-Eve Huteau ◽  
Marta Jarlier ◽  
Hélène de Forges ◽  
Laetitia Meignant ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Patient Education ◽  
Hormonal Therapy ◽  
Patient Adherence ◽  
Adherence Rate ◽  
Yoga Practice ◽  
Therapy Discontinuation ◽  
Adjuvant Breast Cancer ◽  
Articular Pain ◽  
At Home

Background Osteo-articular pain (OAP) is experienced by approximately 50% of women under hormonal therapy (HT) for breast cancer (BC), which increases the risk for therapy discontinuation. This study was aimed to assess benefits of yoga practice combined with patient education (PE) for at-home practice by evaluating feasibility among BC patients under HT and measuring OAP, flexibility and satisfaction. Methods Feasibility was evaluated by patient adherence as accomplishment of at least 4 out of 6 supervised yoga-PE sessions along with 70% or more at-home yoga sessions. Intervention (12 weeks) included two 6-weeks periods: P1 comprising one 90-minutes supervised yoga-PE session/week and 15-minutes daily at-home yoga and P2, daily autonomous at-home yoga sessions. Evaluations (at inclusion and by the end of each period) consisted in assessment of OAP on Visual Analog Scale (VAS), forward flexibility (cm) and patient satisfaction on Likert (0-10 points) scale. Results Between September 2018 and May 2019 we included 24 patients of median 53 years (range 36-72). Feasibility was validated by 83% successful adherence rate. Pain was significantly reduced from median VAS of 6 [range 4-10] to 4 [range 0-7] at the end of both P1 and P2 ( p < 0.01), albeit with no difference between P1 and P2. Forward flexibility improved by a median gain of 8 cm (end of P2) and median satisfaction score of 10/10 [range 8-10]. Conclusion Combined physiotherapy-yoga-PE intervention is a feasible strategy to increase at-home yoga practice with potential benefit on pain, flexibility, and satisfaction, thus prompting further evaluations in larger randomized multicenter trials. ClinicalTrials.gov NCT04001751

Canadian pattern of care for anemia: comparison of chemotherapies in adjuvant breast cancer setting.

2009 ◽  
Author(s):  
A Quinn ◽  
C Wong ◽  
J Younus ◽  
G Dranitsaris ◽  
R Goel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pattern Of Care ◽  
Adjuvant Breast Cancer ◽  
Cancer Setting
Sign in / Sign up

Export Citation Format

Share Document